Skip to content
10-Q

Quarterly Report

SANGAMO THERAPEUTICS, INC SGMO

0001628280-26-035067

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 414.29M sh
Shares Diluted Q1 2026 · Mar 31, 2026 389.62M sh
Shares Diluted Q1 2026 · Mar 31, 2025 220.27M sh
Capex Q1 2026 · Mar 31, 2026 $13K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$19.28M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$26.15M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $27.59M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $20.95M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $25.18M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $41.92M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$18.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$14.27M
Stockholders Equity Q1 2026 · Mar 31, 2025 $4.91M
Stockholders Equity Q1 2026 · Dec 31, 2024 $22.77M
Current Liabilities Q1 2026 · Mar 31, 2026 $53.13M
Current Liabilities Q1 2026 · Dec 31, 2025 $42.47M
Total Liabilities Q1 2026 · Mar 31, 2026 $78.92M
Total Liabilities Q1 2026 · Dec 31, 2025 $74.01M
Current Assets Q1 2026 · Mar 31, 2026 $37.11M
Current Assets Q1 2026 · Dec 31, 2025 $35.83M
Total Assets Q1 2026 · Mar 31, 2026 $59.97M
Total Assets Q1 2026 · Dec 31, 2025 $59.75M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.14
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.14
Sga Expense Q1 2026 · Mar 31, 2026 $6.82M
Sga Expense Q1 2026 · Mar 31, 2025 $10.06M
Rd Expense Q1 2026 · Mar 31, 2026 $26.57M
Rd Expense Q1 2026 · Mar 31, 2025 $26.01M
Net Income Q1 2026 · Mar 31, 2026 −$31M
Net Income Q1 2026 · Mar 31, 2025 −$30.6M
Operating Income Q1 2026 · Mar 31, 2026 −$31.95M
Operating Income Q1 2026 · Mar 31, 2025 −$29.63M
Revenue Q1 2026 · Mar 31, 2026 $1.44M
Revenue Q1 2026 · Mar 31, 2025 $6.44M